Three of the cases have gone to trial. Two resulted in verdicts against the formula companies, totaling $495 million against Abbott Laboratories and $60 million against Mead Johnson. The third ...

Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's debilitating intestinal disease, a jury found on ...

Shares in Reckitt Benckiser topped the Stoxx Europe 600 Index after a U.S. court cleared the company of liability in a case ...

Shares of Abbott Laboratories are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's ...

Abbott said the panel’s finding was consistent with years of studies that found its preterm baby formula was safe. The verdict reinforces the idea “there is no reliable scientific evidence ...

Abbott Laboratories (NYSE:ABT) rose 6% in after hours trading after a jury found the company and a Reckitt Benckiser (OTCPK:RBGPF) unit are not liable over claims the companies' baby formula ...

After the verdict and the "overwhelming societal support of infant formula, we think its prudent to lower the liability exposure and raise the odds of an Abbott victory in the trials, or at least ...

Three of the cases have gone to trial. Two resulted in verdicts against the formula companies, totaling $495 million against Abbott Laboratories and $60 million against Mead Johnson. The third case ...

Shares of Abbott Laboratories and Reckitt Benckiser rose after the companies won a victory in litigation over the safety of some baby-formula products. Abbott shares rose 4% in early New York ...

The trial, which lasted more than a month, was the first time jurors weighed allegations about both Abbott’s Similac formula and Reckitt’s Enfamil in a single case. The case was about a boy born to ...